Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | ALPL | P05186 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.30 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.30 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10310290 | 0.87 | ALOX5 (0.46) | ALOX5MAPTKDM4EROCK2RAB9A | |
| SCHEMBL6692747 | 0.78 | ALPG (0.31) | — | |
| SCHEMBL4854034 | 0.75 | ALOX5 (0.42) | ALOX5MAPTMEN1KMT2AHPGD | |
| SCHEMBL4854667 | 0.75 | — | — | |
| SCHEMBL6694826 | 0.73 | CHRM2 (0.42) | ALOX5MAPTKDM4EMEN1KMT2A | |
| SCHEMBL4846413 | 0.73 | — | — | |
| SCHEMBL14872475 | 0.72 | — | — | |
| SCHEMBL17198839 | 0.72 | NPC1 (0.47) | MAPTKDM4ERAB9AMEN1KMT2A | |
| SCHEMBL4856944 | 0.72 | L3MBTL1 (0.32) | — | |
| SCHEMBL4846961 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7396858-B2 | Biguanide derivative and therapeutic agent for diabetes containing the same | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-07-08 | — | — | US | disclosed |
| EP-1500656-B1 | BIGUANIDE DERIVATIVES AND THEIR USE AS ANTIDIABETIC DRUGS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2007-12-12 | — | — | EP | disclosed |
| US-20050124693-A1 | Biguanide derivative and therapeutic agent for diabetes containing the same | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-06-09 | — | — | US | disclosed |
| EP-1500656-A1 | BIGUANIDE DERIVATIVE AND THERAPEUTIC AGENT FOR DIABETES CONTAINING THE SAME | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124693-A1 | Biguanide derivative and therapeutic agent for diabetes containing the same | SLC5A1, SLC5A2, GLP1R | ALOX5 3114/4885MAPT 4241/4885KDM4E 3416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.